Abstract
Background MFN2 encodes a multifunctional mitochondrial protein best known for its role mitochondrial fusion. While pathogenic variants in MFN2 typically cause Charcot-Marie-Tooth disease subtype 2A, an axonal peripheral neuropathy, exome sequencing identified an uncharacterized MFN2 variant, Q367H, in a patient diagnosed with late-onset distal myopathy without peripheral neuropathy. Although impaired mitochondrial fusion can cause mtDNA-mediated inflammation via TLR9 activation of NF-kB, which is linked to myopathy in a mouse model of MFN1 deficiency, this pathway has not yet been functionally linked to MFN2 pathology.
Methods To investigate if the Q367H MFN2 variant contributes to the patient phenotype, we applied several biochemical and molecular biology techniques to characterize patient fibroblasts and transdifferentiated myoblasts for several functions mediated by MFN2. We also examined TLR9 and cGAS-STING mtDNA-mediated inflammatory pathways.
Findings Patient fibroblasts showed changes consistent with impairment of several MFN2 functions. When grown in standard glucose media, patient fibroblasts had reduced oxidative phosphorylation and elevated levels of lipid droplets. When grown in galactose media, patient fibroblasts had fragmented mitochondria, reduced mito-ER contact sites, and enlarged mtDNA nucleoids. Notably, under both media conditions, mtDNA was present outside of the mitochondrial network, where it co-localized with early endosomes. We also observed activation of both TLR9/NF-kB and cGAS-STING inflammation in fibroblasts. Moreover, the inflammatory signaling was increased 3-10 fold in transdifferentiated patient myoblasts, which also exhibited reduced mito-ER contacts and altered mtDNA nucleoids.
Interpretation We report a patient with myopathy, but without the typical peripheral neuropathy associated with MFN2 disease variants. As elevated inflammation can cause myopathy, linking the Q367H MFN2 variant with elevated TLR9 and cGAS/STING signaling, which is amplified in transdifferentiated myoblasts, provides novel insight into the patient’s phenotype. Thus, we establish a potential novel pathomechanism connecting MFN2 dysfunction to mtDNA-mediated inflammation.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by funds provided by the Alberta Children's Hospital Research Institute (TES), the Canadian Institutes of Health Research (TES), and the New Frontiers Research Fund (TES). MZ was supported by a Hotchkiss Brain Institute International Recruitment Scholarship. WA was supported by the Saudi Cultural Bureau. R.S. was supported by a QEII Graduate Scholarship. TGBS was supported by an Alberta Graduate Excellence Scholarship and a University of Calgary Faculty of Graduate Studies Doctoral Scholarship. MJ is the recipient of the Katharine Sarah Melinda Mei-Ling Thomas Rare Diseases Scholarship. Infrastructure in the lab of GP for this work was supported by the HBI Dementia Research Equipment Fund and a Canada Foundation for Innovation JELF Grant (Neuromuscular Genetics, 36624). The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Genetic sequencing and human tissue studies with this participant were part of research protocols (REB15-2763 and REB17-0850) approved by the Conjoint Health Research Ethics Board at the University of Calgary.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present work are contained in the manuscript
